Evaluation Of Mammographic Features In Women With Adenomyosis

Year 2022, Volume: 39 Issue: 4, 989 - 998, 29.10.2022

Nezaket Kadıoğlu , Ayçağ Yorgancı , Harika Gümgümcü , Mahmut Kuntay Kokanalı , Şebnem Özyer , Yaprak Üstün

Abstract

Abstract
Aim: This study aimed to investigate the mammographic features in women with adenomyosis to determine the relationship between adenomyosis and breast disease.
Methods: In this study, the mammographic features of women with adenomyosis were recorded. For the control group, women who had mammography without any gynaecologic complaints and with normal pelvic ultrasound were selected.
Results: The adenomyosis group had higher breast density, more micro and macro calcifications, and higher BIRADS-mammography classification than the control group. When patients with low mammographic density (Density A - B, n = 80) and high mammographic density (Density C - D, n = 60) were compared, there were no statistically significant differences between the groups except the presence of adenomyosis. When patients were compared according to the BIRADS 1 - 2 (n=114) and BIRADS 3 - 4 (n=26) category, age ≥ 49.5, gravidity ≥ 3, parity ≥ 2, and the presence of adenomyosis were significantly higher in the BIRADS 3 - 4 category. In the logistic regression analysis, the presence of adenomyosis was found to be the sole factor for BIRADS 3-4 category.
Conclusion: The results of our study suggested that patients with adenomyosis have an increased risk of higher mammographic breast density and BIRADS 3 classification.

Keywords

BIRADS, Breast density, Uterine adenomyosis, Gynecology, Mammography

References

• 1.Li X, Liu X, Guo SW.Clinical profiles of 710 premenopausal women with adenomyosis who underwent hysterectomy.J Obstet Gynaecol Res.2014;40(2):485-94.
• 2.Szubert M, Kozirog E, et al.Adenomyosis and Infertility-Review of Medical and Surgical Approaches.Int J Environ Res Public Health.2021;18(3).
• 3.Protopapas A, Grimbizis G, et al.Adenomyosis: Disease, uterine aging process leading to symptoms, or both?Facts Views Vis Obgyn.2020;12(2):91-104.
• 4.Leyendecker G, Bilgicyildirim A, et al.Adenomyosis and endometriosis. Re-visiting their association and further insights into the mechanisms of auto-traumatisation.Arch Gynecol Obstet.2015;291(4):917-32.
• 5.Donnez J, Donnez O, Dolmans MM.Uterine adenomyosis, another enigmatic disease of our time.Fertil Steril.2018;109(3):369-70.
• 6.Bourdon M, Santulli P, et al.Immunological changes associated with adenomyosis: a systematic review.Hum Reprod Update.2021;27(1):108-29.
• 7.Stratopoulou CA, Donnez J, Dolmans MM.Origin and Pathogenic Mechanisms of Uterine Adenomyosis: What Is Known So Far.Reprod Sci.2020.
• 8.Grebic D, Gulic T, et al.The Role of Innate Immunity in the Pathogenesis of Breast Cancer.Breast Care (Basel).2021;16(1):1-5.
• 9.Hilborn E, Stal O, Jansson A.Estrogen and androgen-converting enzymes 17beta-hydroxysteroid dehydrogenase and their involvement in cancer: with a special focus on 17beta-hydroxysteroid dehydrogenase type 1, 2, and breast cancer.Oncotarget.2017;8(18):30552-62.
• 10.Spak DA, Plaxco JS, Santiago L, Dryden MJ, Dogan BE. BI-RADS((R)) fifth edition: A summary of changes. Diagn Interv Imaging.2017;98(3):179-90.
• 11.McCormack VA, dos Santos Silva I. Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev.2006;15(6):1159-69.
• 12.Boyd NF, Martin LJ, et al. Breast tissue composition and susceptibility to breast cancer.J Natl Cancer Inst.2010;102(16):1224-37.
• 13.Kerlikowske K, Cook AJ, Buist DS, Cummings SR, Vachon C, Vacek P, et al. Breast cancer risk by breast density, menopause, and postmenopausal hormone therapy use.J Clin Oncol.2010;28(24):3830-7.
• 14.Boyer B, Canale S, et al. Variability and errors when applying the BIRADS mammography classification.Eur J Radiol.2013;82(3):388-97.
• 15.Berg WA, Berg JM, et al. Cancer Yield and Patterns of Follow-up for BI-RADS Category 3 after Screening Mammography Recall in the National Mammography Database.Radiology.2020;296(1):32-41.
• 16.Nagasawa H KR, Naito T, Ohmiya S, Mori T. Relationship between mammary tumourigenesis and uterine adenomyosis in four strains of mice.In Vivo.1987;1(4):237-40.
• 17.Huseby RA SM, Talamantes F. Ectopic Pituitary Grafts in Mice: Hormone Levels, Effects on Fertility, and the Development of Adenomyosis Uteri, Prolactinomas, and Mammary Carcinomas.Endocrinology.1985;116(4):1440-8.
• 18.Nagasawa H, Naito T. Enhanced potentials for mammary tumourigenesis and uterine adenomyosis in (SLN x C3H/He)F1 virgin mice.Lab Anim.1992;26(1):23-4.
• 19.Cohen I, Beyth Y, et al. Adenomyosis in postmenopausal breast cancer patients treated with tamoxifen: a new entity?Gynecol Oncol.1995;58(1):86-91.
• 20.Cohen I, Beyth Y, et al. High frequency of adenomyosis in postmenopausal breast cancer patients treated with tamoxifen.Gynecol Obstet Invest.1997;44(3):200-5.
• 21.Kitawaki J, Noguchi T, et al. Expression of aromatase cytochrome P450 protein and messenger ribonucleic acid in human endometriotic and adenomyotic tissues but not in normal endometrium.Biol Reprod.1997;57(3):514-9.
• 22.Rizner TL. The Important Roles of Steroid Sulfatase and Sulfotransferases in Gynecological Diseases.Front Pharmacol.2016;7:30.
• 23.Kitawaki J, Koshiba H, et al. Progesterone induction of 17beta-hydroxysteroid dehydrogenase type 2 during the secretory phase occurs in the endometrium of estrogen-dependent benign diseases but not in normal endometrium.J Clin Endocrinol Metab.2000;85(9):3292-6.
• 24.Chen YJ, Li HY, et al. Oestrogen-induced epithelial-mesenchymal transition of endometrial epithelial cells contributes to the development of adenomyosis.J Pathol.2010;222(3):261-70.
• 25.Leyendecker G, Wildt L. A new concept of endometriosis and adenomyosis: tissue injury and repair (TIAR).Horm Mol Biol Clin Investig.2011;5(2):125-42.
• 26.Sang X, Han H, Poirier D, Lin SX. Steroid sulfatase inhibition success and limitation in breast cancer clinical assays: An underlying mechanism.J Steroid Biochem Mol Biol.2018;183:80-93.
• 27.Peleg Hasson S et al. Adjuvant endocrine therapy in HER2-positive breast cancer patients: systematic review and meta-analysis. ESMO Open. 2021;6(2):100088.
• 28.Kok VC, Tsai HJ, Su CF, Lee CK. The Risks for Ovarian, Endometrial, Breast, Colorectal, and Other Cancers in Women With Newly Diagnosed Endometriosis or Adenomyosis: A Population-Based Study. Int J Gynecol Cancer. 2015;25(6):968-76.
• 29.Yeh CC, Su FH, Tzeng CR, Muo CH, Wang WC. Women with adenomyosis are at higher risks of endometrial and thyroid cancers: A population-based historical cohort study. PLoS One. 2018;13(3):e0194011.